MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells by unknown
Yu et al. BMC Cancer  (2015) 15:29 
DOI 10.1186/s12885-015-1031-5RESEARCH ARTICLE Open AccessMiR-130b plays an oncogenic role by repressing
PTEN expression in esophageal squamous cell
carcinoma cells
Tingting Yu1†, Risheng Cao1†, Shuo Li1†, Mingen Fu1, Lihua Ren1, Weixu Chen1, Hong Zhu1, Qiang Zhan2*
and Ruihua Shi1,3*Abstract
Background: Esophageal carcinoma is one of the most common malignancies with high cancer-related morbidity
and mortality worldwide. MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate a wide variety of
cellular processes, and also play an important role in the development and progression of cancers. In a previous
microarray study, we demonstrated that miR-130b was upregulated in esophageal squamous cell carcinoma
(ESCC) tissues. However, the biologic functions and the molecular mechanism of miR-130b in ESCC remain to
be elucidated.
Methods: qRT-PCR assays were used to quantify miR-130b expression levels in ESCC samples. Novel targets of
miR-130b were identified via a bioinformatics search and confirmed using a dual-luciferase reporter system.
Western blotting and qRT-PCR assays were used to quantify the expression of the target gene PTEN (phosphatase and
tensin homolog) and the downstream effector, Akt. ESCC cells over- or underexpressing miR-130b were analyzed for
in vitro biologic functions.
Results: High levels of miR-130b were identified in 20 ESCC samples following comparison with adjacent
non-neoplastic tissues. We confirmed that miR-130b interacted with the 3′-untranslated region of PTEN, and that an
increase in the expression level of miR-130b negatively affected the protein level of PTEN. However, the dysregulation
of miR-130b had no obvious impact on PTEN mRNA. As Akt is a downstream effector of PTEN, we explored if miR-130b
affected Akt expression, and found that miR-130b indirectly regulated the level of phosphorylated Akt, while total Akt
protein remained unchanged. Overexpression of miR-130b increased the proliferation of ESCC cells and enhanced their
ability to migrate and invade. In contrast, the proliferation, migration, and invasion of ESCC cells were weakened when
miR-130b expression was suppressed, which was reversed by PTEN-targeted siRNA.
Conclusion: The results indicate that miR-130b plays an oncogenic role in ESCC cells by repressing PTEN expression
and Akt phosphorylation, which would be helpful in developing miRNA-based treatments for ESCC.
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Table 1 Clinical features of 3 ESCC patients for subjection
of Agilent microarray analysis and 20 patients for
qRT-PCR validation
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Esophageal carcinoma is one of the most common malig-
nancies with high cancer-related morbidity and mortality
worldwide. Esophageal squamous cell carcinoma (ESCC)
and esophageal adenocarcinoma are the two major histo-
logic types of esophageal carcinoma [1]. The incidence of
esophageal carcinoma shows significant regional differ-
ences [2]. Notably, the incidence of ESCC is particularly
high in the so-called Asian belt, which includes Turkey,
northeastern Iran, Kazakhstan, and northern and central
China, with more than 100 cases per 100,000 people re-
ported annually [3]. The carcinogenesis of ESCC is pro-
posed as a multistep process. Previous studies have shown
that tobacco and alcohol consumption are associated with
a higher risk of ESCC [4]. Other risk factors include low
socioeconomic status, nutritional deficiencies, excess in-
take of hot beverages and genetic predisposition [5,6]. Al-
though diagnostic and treatment methods have been
developed in recent years, the five-year overall survival of
ESCC remains < 14% [1]. Therefore, more specific and
sensitive biomarkers for diagnosis and targeted therapy of
ESCC are urgently needed.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that are 17–24 nucleotides in length [7]. It is esti-
mated that more than 50% of the miRNAs are located in
cancer-related regions and fragile sites of chromosomes
[8]. Increasing evidence shows that dysregulation of
miRNAs leads to the development and progression of
cancers [9]. The up- or downregulation of miRNAs is
correlated with specific tumor types; different human
cancers have distinct miRNA expression profiles [10].
Studies have shown that aberrant expression of miRNAs
affects cell proliferation, apoptosis, metastasis, and sen-
sitivity to chemotherapy and radiotherapy in multiple
cancers [11]. This highlights the potential for using ex-
pression profiles of specific miRNAs for cancer diagnosis
or therapy.
MiR-130b, located at the 22q11 locus [12], plays an
oncogenic role in gastric, liver, and endometrial cancers
[13-15], and acts as a tumor suppressor in ovarian cancer
and thyroid papillary carcinoma [16,17]. A recent study
revealed a correlation between miR-130b and prognoses
of postoperative esophageal cancer patients, and suggested
that upregulation of miR-130b might be an unfavorable
factor for ESCC patients [18]. However, the expression
levels and the functions of miR-130b in ESCC have not
been reported so far. In the present study, we explored the
regulation of miRNAs that may be involved in the devel-
opment and progression of ESCC. We analyzed miRNA
expression profiles in matched primary ESCC and corre-
sponding normal esophageal tissues via miRNA micro-
array analysis and quantitative real-time PCR (qRT-PCR).
A dual-luciferase reporter assay was used to verify that
phosphatase and tensin homolog (PTEN) is a downstreamtarget of miR-130b. Functional analyses regarding cell pro-
liferation, migration, and invasion were performed to in-
vestigate the effect of miR-130b expression on ESCC cells
in vitro.
Methods
Cell lines and clinical samples
Matched ESCC and corresponding adjacent normal esopha-
geal tissues were obtained from 23 patients who underwent
esophagectomy for primary ESCC in the First Affiliated
Hospital of Nanjing Medical University (Table 1). None of
the patients had received preoperative chemotherapy or
radiotherapy. All tissue samples were frozen in liquid ni-
trogen immediately after resection and stored at −80°C.
The histologic diagnosis of these tissue samples was con-
firmed by a pathologist. This study was approved by the
Committee for Ethical Review of Research at the First
Affiliated Hospital of Nanjing Medical University, and
informed consent was obtained from all the patients in-
volved. The human ESCC cell lines, Eca109 and TE13,
were purchased from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China).
Cell culture and transfection
Eca109 and TE13 cell lines were cultured in Roswell Park
Memorial Institute (RPMI)-1640 or Dulbecco’s modi-
fied eagle media (Wisent Inc., Quebec, Canada) supple-
mented with 10% fetal bovine serum (Wisent Inc.) and 1%
penicillin-streptomycin (Invitrogen of Thermo Fisher
Scientific Inc., Waltham, MA, USA) in a humidified
5% CO2 atmosphere at 37°C. The miR-130b mimic (miR-
130bm), negative control of miRNA mimic (NC), miR-130b
inhibitor (miR-130bi), negative control of miRNA inhibitor
(iNC) and PTEN-targeted small interfering RNA (siPTEN)
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transfected at a final concentration of 50–100 nM with
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. After 6 h, the cells were returned
to normal medium and cultured for an additional 48 (for
RNA isolation) or 72 h (for protein extraction). The inhib-
ition efficiency of siPTEN was also determined (Additional
file 1).
MiRNA microarray analysis
Total RNA was isolated from matched ESCC and corre-
sponding normal esophageal epithelium tissues (n = 3)
with TRIzol (Invitrogen) according to the manufacturer’s
instructions. The RNA concentration was measured on
a Nanodrop 2000 spectrophotometer (Thermo Fisher
Scientific), and the quality of the RNA was examined on
a denaturing formaldehyde gel. The RNA was purified
(mirVana miRNA Isolation Kit; Ambion of Thermo Fisher
Scientific), and 200 ng from each tissue sample was la-
beled and hybridized (miRNA Complete Labeling and
Hyb Kit; Agilent Technologies, Santa Clara, CA, USA) on
a miRNA microarray chip (G4870A; Agilent Technologies)
encompassing 1205 human and 142 viral miRNA probes.
The data were transformed from the hybridization picture
with Feature Extraction software v10.7 and integrated
using GeneSpring software (Agilent Technologies).
qRT-PCR
RNA was isolated from ESCC tissue samples and cells as
described above and cDNA was synthesized using a
TaqMan microRNA Reverse Transcription Kit (Applied
Biosystems of Thermo Fisher Scientific) according to the
manufacturer’s instructions. The expression level of mature
miR-130b in the tissues or the ESCC cells was confirmed
by a TaqMan microRNA assay (Applied Biosystems). Levels
of PTEN mRNA in ESCC cells were quantified using SYBR
Green real-time PCR master mix (Applied Biosystems)






CTTCCACG-3′ (reverse). The relative expression levels
of mature miR-130b and PTEN mRNA were calculated
by the 2-ΔΔCt method and normalized to U6 snRNA and
GAPDH mRNA levels, respectively. All PCR reactions
were performed on a StepOne Plus RT-PCR instrument
(Applied Biosystems).
Dual-luciferase reporter assay
A 59 bp fragment from the 3′-untranslated region (UTR)
of PTEN containing the putative binding sequences for
miR-130b was synthetized cloned into the firefly luciferasepGL3-control vector (Invitrogen). For the reporter assay,
Eca109 cells (in logarithmic growth phase) were plated
in a 24-well culture plate at a density of 8000 cells/well.
The cells in each well were co-transfected with 25 nM of
miR-130bm, miR-130bi or NC, 800 ng/μL of miR-130b-
pGL3 vector and 0.8 ng/μL of pRL-TK vector (Invitrogen)
using Lipofectamine 2000 according to the manufacturer’s
instructions. The cell lysates were collected 24 h after
transfection. The firefly and Renilla luciferase activities
were measured using the dual-luciferase reporter assay
system (Promega Corp., Madison, WI, USA). The lucif-
erase activity was detected on a GLOMAX20/20 lumin-
ometer (Promega Corp.) and normalized to the Renilla
luciferase activity.
Western blot analysis
Proteins were extracted from harvested Eca109 and
TE13 cells using radioimmunoprecipitation assay buffer
(Beyotime, Beijing, China) according to the manufacturer’s
instructions. Equal amounts of protein lysates (30 μg)
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) on a 10% gel and trans-
ferred to a nitrocellulose membrane. The membranes
were blocked with 5% non-fat milk in TBST (10 mM
Tris–HCl [pH 8.0], 150 mM NaCl, and 0.05% Tween-20)
for 1 h at room temperature, and incubated overnight
with agitation at 4°C with primary antibodies against hu-
man PTEN, Akt, p-Akt (1:1000; Cell Signaling Technology
Inc., Danvers, MA, USA), and GAPDH (1:6000; Bioworld,
Visalia, CA, USA). The membranes were washed and in-
cubated with goat anti-rabbit IgG secondary antibody
(1:5000; Santa Cruz Biotechnology, Dallas, TX, USA) for
1 h. The immunoreactivity was assessed on a gel-imaging
analyzer (Bio-Rad Laboratories Inc., Hercules, CA, USA).
The band densities of PTEN, Akt and p-Akt were mea-
sured using Image Lab software (Bio-Rad Laboratories,
Inc.) and normalized to GAPDH.
Cell proliferation assay
The transfected cells that were in the logarithmic growth
phase were seeded into 96-well plates at a cell density of
2000 cells/well for Eca109 and 5000 cells/well for TE13.
Five wells were set up for each transfected group. Cell
counting kit-8 (CCK-8) solution (10 μL) was added to
one well in each group every 24 h for four consecutive
days, incubated at 37°C for 2 h, and the optical density
was measured at 450 nm on a microplate reader
(Thermo Fisher Scientific Inc.). The proliferation curve
was determined using the average optical density values
of each group.
Colony formation assay
After transfection, approximately 300 Eca109 cells were
added to each well of 6-well plates and incubated at
Table 2 The miRNA microarray data of highly
upregulated (fold-change > 5.0) miRNAs in esophageal
squamous cell carcinoma (ESCC) tissues compared with
normal esophageal tissues
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week and replaced with fresh medium. On day 14, the
cells were washed twice with PBS, fixed with methanol for
30 min and stained with crystal violet staining solution
(Beyotime, Beijing, China) for 30 min. The dishes were
washed with PBS three times and air-dried. The colonies
that contained > 50 cells were counted and the colony
forming efficiency was calculated.
Anchorage-independent growth ability assay in soft agar
Two thousand Eca109 cells were trypsinized and sus-
pended in 2 mL complete medium plus 0.3% agar
(Becton, Dickinson and Co., Franklin Lakes, NJ, USA).
The agar–cell mixture was plated on top of a bottom layer
with 0.6% complete medium agar mixture. After 2 wk, vi-
able colonies that contained ≥ 50 cells or were > 50 μm in
diameter were counted.
Transwell migration and invasion assays
For the cell migration assay, Transwell chambers (EMD
Millipore, Billerica, MA, USA) with 8.0-μm-pore-size
basement membranes were placed into a 24-well culture
plate. For the cell invasion assay, the upper surface of the
membrane was evenly covered with 50 μL of 1 mg/mL
Matrigel (Becton, Dickinson and Co.). Briefly, 200 μL
serum-free cell suspension containing 1 × 105 Eca109 cells
was added to the upper compartment of the chamber,
and the lower compartment was filled with RPMI-1640
medium containing 10% fetal bovine serum as a chemo-
attractant. After incubation at 37°C for 48 h, the cells were
fixed with 75% ethanol and stained with crystal violet
staining solution. Non-migrating cells on the upper sur-
face of the membrane were removed with cotton swabs.
The migratory and invasive cells in each chamber were
counted from at least five randomly chosen high power
fields.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA). The expression of
miR-130b in ESCC and matched normal esophageal
tissues was analyzed by paired-samples t-test, and
independent-samples t-tests were used for other data
analyses; P < 0.05 was considered statistically significant.
All data from this study were obtained from at least three
independent experiments and are expressed as mean ±
SEM.
Results
MiR-130b is overexpressed in ESCC tissues
To determine the effect of miRNAs on the development
and progression of ESCC, we first performed a miRNA
microarray analysis (cutoff, > 2.0 fold-change). The results
of the microarray analysis, which had been depositedto Gene Expression Omnibus (GEO) database [GEO:
GSE59973], showed that 51 miRNAs were significantly
overexpressed in ESCC tissues when compared with
normal esophageal tissues, including miR-130b, which
showed a fivefold-change over the normal esophageal tis-
sues (Table 2). Quantification of miR-130b expression in
20 ESCC and matched normal esophageal tissue samples
confirmed the microarray results (Figure 1).
PTEN is a target of miR-130b
By integrating the search results of TargetScan and miRDB
programs (Figure 2A), we identified the tumor suppressor
gene PTEN as a potential target of miR-130b. A dual-
luciferase reporter assay was performed to verify that the
3′-UTR of PTEN mRNA is a direct target of miR-130b.
The luciferase activity of Eca109 cells transfected with
miR-130bm was reduced by approximately 60% when
compared to the NC transfected cells, whereas miR-130bi
increased the activity (Figure 2B).
MiR-130b regulates expression of PTEN and
phosphorylation of Akt
To investigate the possible underlying molecular mech-
anism of miR-130b in ESCC tissues, Eca109 and TE13
cells were transfected with miR-130bm and miR-130bi
to increase and decrease miR-130b expression, respect-
ively. PTEN targeted siRNA was also co-transfected with
miR-130bi to identify the effect of PTEN protein ex-
pression. Western blotting (Figure 3A–D) and qRT-PCR
(Figure 3G, H) analyses showed that miR-130b negatively
regulated levels of PTEN protein but not mRNA, indicat-
ing regulation at the translational level.
PTEN is the main negative regulator of the phos-
phatidylinositol 3 kinase/Akt pathway [19]. Therefore,
we explored whether miR-130b regulation of PTEN pro-
tein levels affects Akt phosphorylation. Western blotting
showed that upregulation of miR-130b was accompanied
by an increase in the levels of phosphorylated Akt
(p-Akt) (Figure 3A,B,E,F). Conversely, p-Akt levels de-
creased when the expression of miR-130b was suppressed.
Figure 1 Expression of mature miR-130b in ESCC tissue specimens.
The expression of miR-130b was detected by TaqMan qRT-PCR in 20
ESCC and matched normal esophageal tissue samples. The expression
of miR-130b is presented on a 2-ΔCT (×100) scale and normalized
against the endogenous control U6. (A) Paired comparison of
miR-130b expression in ESCC tissue and matched normal tissue.
(B) Scatter plots with merged data.
Figure 2 Identification of PTEN as target of miR-130b. (A)
Bioinformatic prediction by TargetScan indicated that PTEN mRNA
contains a putative miR-130b binding region, located at 412–418 nt
of 3′-UTR. (B) A dual-luciferase reporter assay was used to confirm
the interaction of miR-130b with PTEN. A fragment of miR-130b that
was predicted to bind to the PTEN 3′-UTR was cloned into firefly
luciferase pGL3-control vector. The Renilla luciferase plasmid was
co-transfected for normalizing luciferase activity. *P< 0.05, **P< 0.01 vs.
corresponding controls.
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indicating that miR-130b regulates the phosphorylation of
Akt, rather than the protein expression.
MiR-130b regulates the proliferation of ESCC cells
We used CCK-8 and colony formation assays to examine
the proliferative ability of ESCC cells. Cell growth curves
were constructed from CCK-8 absorbances in Eca109 and
TE13 cells at 24, 48, 72 and 96 h, showing that the rate of
cell growth in the miR-130bm transfected group was sig-
nificantly increased compared with NC groups (P < 0.05)
(Figure 4A-D). In contrast, the viability of ESCC cells was
inhibited following transfection with miR-130bi, which was
reversed by co-transfection with a PTEN-targeted small inter-
fering RNA. Similar results were obtained from colony for-
mation and soft-agar assays in Eca109 cells (Figure 4E–H).
MiR-130b promotes ESCC cell migration and invasion in vitro
Tumor cell migration and invasion are one of the lead-
ing causes of tumor metastasis. Therefore, we addressedwhether miR-130b affects the ability of Eca109 cells to
migrate and invade. Overexpression of miR-130b signifi-
cantly increased the number of cells capable of migration
and invasion (P < 0.05) (Figure 5). Moreover, inhibition of
PTEN expression rescued the decreased cell migration
and invasion capacities induced by miR-130bi.
Discussion
A better understanding of the mechanisms underlying
the carcinogenesis of ESCC is important for developing
more effective diagnostic and therapeutic strategies. As
studies on ESCC advanced, they were no longer limited
to oncogenes or tumor suppressor genes, and extended
to include entire signaling pathways and gene interaction
networks. MiRNAs affect a variety of cellular pathways,
and a single miRNA can target multiple genes [20,21].
This specific characteristic of miRNAs has made them a
topic of intense research in recent years.
It is estimated that miRNAs regulate the expression of
30–60% of human genes [20,22]. MiRNAs regulate gene
expression at the transcriptional or translational level by
binding to the 3′-UTR of mRNAs [23]. Whether a miRNA
acts as a tumor promoter or repressor depends on the
gene that it interacts with [24]. Previous studies have re-
ported associations of miR-130b with some types of solid
tumors. For example, miR-130b is significantly overex-
pressed in gastric cancers, which increases cell viability
and decreases the expression of runt related transcription
factor 3 gene and Bim during transforming growth factor
Figure 3 MiR-130b regulates the expression of PTEN and phosphorylation of Akt. Eca109 and TE13 cells were transfected with miR-130b
mimic (130bm group) or inhibitor (130bi group); siPTEN was also co-transfected with the miR-130b inhibitor to decrease PTEN expression (130bi +
siPTEN group). Protein expression of PTEN, p-Akt and total Akt in Eca109 (A, C, E) and TE13 cells (B, D, F) was determined by Western blot
analysis. PTEN mRNA expression was detected by SYBR Green real-time PCR at 24 h following transfection of Eca109 (G) and TE13 (H) cell
lines. The values were normalized to the corresponding controls. GAPDH was the endogenous control. *P < 0.05, **P < 0.01 vs. corresponding controls;
#P < 0.05 vs. 130bi group.
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miR-130b promotes CD133+ liver tumor-initiated cell
growth and self-renewal in vitro and in vivo via tumor
protein 53-induced nuclear protein 1 [15]. The expression
of miR-130b is increased in hyperplastic endometriumand increases even further in endometrial cancer, which,
along with DICER1 dysfunction, leads to tumor aggression
both in vitro and in vivo [14]. In contrast, miR-130b is
downregulated in ovarian cancer and papillary thyroid car-
cinoma, and its expression is inversely correlated with the
Figure 4 Effect of miR-130b on the proliferation of ESCC cells in vitro. The viability of Eca109 and TE13 cells transfected with miR-130b
mimic, negative control, miR-130b inhibitor, inhibitor negative control or siPTEN was detected by CCK-8 at 24, 48, 72 and 96 h. The absorbance
was measured at 450 nm. (A, B) Proliferation curves of Eca109 cells. (C, D) Proliferation curves of TE13 cells. For colony formation (E, G) and
soft-agar (F, H) assays in Eca109 cells, the following calculation was performed: colony-forming efficiency (%) = the number of colonies
(>50 cells or larger than 50 μm)/the number of cells plated per well. The photographs were captured from digital camera or microscope
at 40× magnification, in which the size bar was representative of 200 μm. The results are expressed as mean ± SEM of three independent
experiments. *P < 0.05, **P < 0.01 vs. corresponding controls; #P < 0.05, ##P < 0.01 vs. 130bi group.
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cancers [16,17].
Recently, the first research report showing a correlation
between miR-130b and ESCC in a study comparing ESCCpatients with the same tumor node metastasis stage but
different prognoses [18]. Their results demonstrated that
miR-130b was significantly downregulated in the paracan-
cerous normal esophageal mucous membranes of patients
Figure 5 MiR-130b regulates the migration and invasion of ESCC cells. 1 × 105 Eca109 cells were added to the Transwell inserts. For the
invasion assay, the wells were covered with 50 μL of 1 mg/mL Matrigel. Cells were transfected with miR-130b mimic, negative control, miR-130b
inhibitor, inhibitor negative control or siPTEN. The migratory or invasive cells were counted from five random areas at 200× magnification. (A) Cell
images captured by microscopy. (B) Histogram of cell migration results. (C) Histogram of cell invasion results. The results are presented as mean ±
SEM from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. corresponding controls; #P < 0.05, ##P < 0.01 vs. 130bi group.
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parate tumor-associated roles that are likely related to dif-
ferences in tumor types and genes targeted. To date, no
published study has focused on the functions and molecu-
lar mechanisms of miR-130b in ESCC. In our study,
miRNA microarray analysis and qRT-PCR confirmed that
miR-130b is overexpressed in ESCC tissues. Furthermore,
increased expression of miR-130b promoted proliferation,
migration and invasion in vitro, whereas these abilities
were weakened when miR-130b was inhibited.
PTEN is located at 10q23.3 and encodes a dual-specificity
phosphatase with lipid and protein phosphatase activ-
ities. PTEN dephosphorylates PI(3,4,5)P3, an important
activator of Akt [25], which controls a variety of cellular
processes, such as survival, cell cycle progression, metab-
olism, and angiogenesis [26]. Inhibition of PTEN results
in increased levels of activated p-Akt [19]. Decreased ex-
pression of PTEN in ESCC is correlated with prognosis
[27,28]. The proliferation of ESCC cells in vitro and
in vivo is promoted by transfections with PTEN expres-
sion vectors [29]. Moreover, PTEN is frequently mutated
or there is loss of heterozygosity in multiple malignancies,
but these occur rarely in ESCC [30,31]. Several studies
have reported that certain miRNAs can directly target
PTEN [25]. MiR-21 was among the earliest miRNAs forwhich it was confirmed that its suppression increased
PTEN levels and decreased tumor cell proliferation, mi-
gration, and invasion in human hepatocellular cancer [32].
Subsequent studies indicated that PTEN is a potential tar-
get of miR-221/222, miR-22 and miR-144 in different ma-
lignancies [33-35]. Our study shows that miR-130b binds
the 3′-UTR of PTEN mRNA to downregulate PTEN
protein expression, thus promoting Akt phosphorylation.
Moreover, silencing of PTEN expression reversed the effect
of miR-130bi on cell proliferation, invasion and migration.
Conclusion
In summary, our study reveals that miR-130b is overex-
pressed in ESCC tissues. PTEN is a target of miR-130b,
which regulates expression at the translational level. Suppres-
sion of PTEN results in increased p-Akt, promoting the pro-
liferation, migration and invasion of ESCC cells in vitro. Our
findings suggest that miR-130b may be a new target for
ESCC diagnosis and therapy. However, the clinical sample
size in this study was limited and the investigation of
miR-130b function in ESCC was restricted to in vitro experi-
ments. To further confirm the role of miR-130b in car-
cinogenesis, the expression level of miR-130b should be
compared among a larger number of clinical specimens with
different pathologic gradings, and also in animal models.
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Additional file 1: The inhibition efficiency of PTEN targeted siRNA.
Eca109 and TE13 cells were transfected with PTEN targeted siRNA (siPTEN)
and negative control (NC) as described in the Methods section. Western
blot analysis and qRT-PCR were performed to determine the protein
(A) and mRNA (B) expression of PTEN. GAPDH was the endogenous
control. The results are expressed as mean ± SEM of three independent
experiments. ***P < 0.001 vs. corresponding controls.
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